
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is a clinical-stage biopharmaceutical company with a positive outlook as it focuses on developing novel therapeutics for unmet medical needs. Its lead drug candidates, lasofoxifene and ATH-1105, show promising results for the treatment of metastatic breast cancer and ALS. The company's strategy of combining its drugs with other treatments could position them as a top choice for physicians in the evolving 2L ER+/HER2-mBC market, potentially leapfrogging other novel endocrine therapies. With strong clinical data and a well-funded pipeline, LeonaBio's stock is undervalued compared to its potential market share and potential label expansions.
Bears say
LeonaBio is a clinical-stage biopharmaceutical company that has demonstrated positive results with its novel drugs lasofoxifene and ATH-1105 in their respective clinical trials. However, the company's former program for Alzheimer's Disease failed to meet endpoints, raising concerns about the success of their current and future drug candidates. Additionally, while the company has raised significant funding through an IPO and equity financing, it has yet to generate any revenue, making it a risky investment at this stage.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares